Seno

Seno Medical Earns Frost & Sullivan's 2023 United States Enabling Technology Leadership Award for Delivering a More Efficient Breast Cancer Diagnosis with Its Cutting-edge Technology

Retrieved on: 
Wednesday, January 17, 2024
Artificial intelligence, Mammography, Research, Health, SAN, Orientation, Deep learning, Frost, Breast cancer, Malignancy, Food, Seno, Medicine, FDA, Organization, PMA, Breast, Diagnosis, Medical imaging

SAN ANTONIO, Jan. 17, 2024 /PRNewswire/ -- Frost & Sullivan recently recognized Seno Medical with the 2023 US Enabling Technology Leadership Award. Seno Medical is a groundbreaking company founded in 2005 that revolutionized the breast cancer imaging sector with its innovative opto-acoustic/ultrasound (OA/US) technology, integrating laser optics with ultrasound to enhance cancer diagnosis.

Key Points: 
  • Seno Medical offers highly differentiated opto-acoustic/ultrasound (OA/US) exam to diagnose breast cancer and significantly reduce unnecessary breast biopsies.
  • SAN ANTONIO, Jan. 17, 2024 /PRNewswire/ -- Frost & Sullivan recently recognized Seno Medical with the 2023 US Enabling Technology Leadership Award.
  • Seno Medical is a groundbreaking company founded in 2005 that revolutionized the breast cancer imaging sector with its innovative opto-acoustic/ultrasound (OA/US) technology, integrating laser optics with ultrasound to enhance cancer diagnosis.
  • Seno Medical's trendsetting approach lies in the ability of its advanced breast cancer diagnosis technology to address critical industry challenges, such as staff shortages and the high rate of unnecessary biopsies.

Seno Medical Earns Frost & Sullivan's 2023 United States Enabling Technology Leadership Award for Delivering a More Efficient Breast Cancer Diagnosis with Its Cutting-edge Technology

Retrieved on: 
Wednesday, January 17, 2024
Artificial intelligence, Mammography, Research, Health, SAN, Orientation, Deep learning, Frost, Breast cancer, Malignancy, Food, Seno, Medicine, FDA, Organization, PMA, Breast, Diagnosis, Medical imaging

SAN ANTONIO, Jan. 17, 2024 /PRNewswire/ -- Frost & Sullivan recently recognized Seno Medical with the 2023 US Enabling Technology Leadership Award. Seno Medical is a groundbreaking company founded in 2005 that revolutionized the breast cancer imaging sector with its innovative opto-acoustic/ultrasound (OA/US) technology, integrating laser optics with ultrasound to enhance cancer diagnosis.

Key Points: 
  • Seno Medical offers highly differentiated opto-acoustic/ultrasound (OA/US) exam to diagnose breast cancer and significantly reduce unnecessary breast biopsies.
  • SAN ANTONIO, Jan. 17, 2024 /PRNewswire/ -- Frost & Sullivan recently recognized Seno Medical with the 2023 US Enabling Technology Leadership Award.
  • Seno Medical is a groundbreaking company founded in 2005 that revolutionized the breast cancer imaging sector with its innovative opto-acoustic/ultrasound (OA/US) technology, integrating laser optics with ultrasound to enhance cancer diagnosis.
  • Seno Medical's trendsetting approach lies in the ability of its advanced breast cancer diagnosis technology to address critical industry challenges, such as staff shortages and the high rate of unnecessary biopsies.

Alex Hamlow Joins Seno Medical as Chief Revenue Officer

Retrieved on: 
Friday, September 22, 2023
BS, Malignancy, Education, Supplement, Chief commercial officer, Cancer, Woman, Breast, Google Images, Electronic, Certification, Radiology, DeVry University, X-ray, Electronic engineering, Patient, Physician, Seno, Growth, Diagnosis, Hypoxia, Breast cancer, Medical imaging

San Antonio, TX, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Alex Hamlow has joined Seno Medical Instruments, Inc. as Chief Revenue Officer.

Key Points: 
  • San Antonio, TX, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Alex Hamlow has joined Seno Medical Instruments, Inc. as Chief Revenue Officer.
  • Seno Medical is the leader in improving the process of diagnosing breast cancer and the pioneer of the Imagio® Breast Imaging System with opto-acoustic/ultrasound (OA/US) imaging technology.
  • “Alex’s experience scaling businesses and cementing global growth is a perfect fit for Seno Medical,” said Tom Umbel, CEO of Seno Medical.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to developing and commercializing a new modality in cancer diagnosis: opto-acoustic imaging.

Seno Medical Adds Agnes Berzsenyi to Board of Directors

Retrieved on: 
Thursday, September 14, 2023
General Electric, GE HealthCare, Health, Cancer, Woman, Breast, Risk, Seno, Diagnosis, Mammography, Breast cancer, Medical imaging

San Antonio, TX, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Seno Medical Instruments, Inc., the leader in improving the process of diagnosing breast cancer and the pioneer of the Imagio® Breast Imaging System with opto-acoustic/ultrasound (OA/US) imaging technology, has added Agnes Berzsenyi to its Board of Directors, effective immediately.

Key Points: 
  • San Antonio, TX, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Seno Medical Instruments, Inc., the leader in improving the process of diagnosing breast cancer and the pioneer of the Imagio® Breast Imaging System with opto-acoustic/ultrasound (OA/US) imaging technology, has added Agnes Berzsenyi to its Board of Directors, effective immediately.
  • Ms. Berzsenyi spent over 27 years at General Electric, where she held prominent leadership positions driving disruptive innovation, global growth and profitability.
  • In her most recent role, Ms. Berzsenyi was the President and CEO, Women's Health & X-ray, for GE Healthcare.
  • “Agnes brings passion with a deep and vast background in Women’s Health to her new role on Seno Medical’s Board.

Seno Medical’s SenoGram® Decision Support Tool Named Winner in 2023 Artificial Intelligence Excellence Awards

Retrieved on: 
Thursday, March 23, 2023
X-ray, Malignancy, Life, Minnie Sarwal, Supplement, Cancer, Diagnosis, Google Images, Certification, Organization, Radiology, Breast mass, Patient, Physician, Gold, Seno, Artificial intelligence, Hypoxia, Medical imaging

San Antonio, TX, March 23, 2023 (GLOBE NEWSWIRE) -- The Artificial Intelligence Excellence Awards program has selected Seno Medical’s AI platform, SenoGram® — exclusively available in conjunction with the company’s Imagio® Breast Imaging System — as a winner in its first annual program.

Key Points: 
  • San Antonio, TX, March 23, 2023 (GLOBE NEWSWIRE) -- The Artificial Intelligence Excellence Awards program has selected Seno Medical’s AI platform, SenoGram® — exclusively available in conjunction with the company’s Imagio® Breast Imaging System — as a winner in its first annual program.
  • SenoGram® is an artificial intelligence (AI) decision-support tool that helps physicians interpret new images from the Imagio® System.
  • The Artificial Intelligence Excellence Awards recognizes those organizations, products, and people who bring AI to life and apply it to solve real problems.
  • Awards are broken down by categories; the SenoGram® AI decision-support tool was recognized in the Diagnosis category.

Seno Medical Inks Exclusive Agreement with Genetik, Inc. as Distributor for Imagio® Breast Imaging System in Southeast Asia

Retrieved on: 
Friday, January 13, 2023
X-ray, Supplement, Seno, Standard of care, Certification, Gold, Breast, FDA, Malignancy, Radiology, Stavros S Niarchos, Hypoxia, Google Images, Artificial intelligence, Breast mass, Patient, Cancer, PMA, Breast cancer, Physician, Medical imaging, Genetiks

San Antonio, TX, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Seno Medical has entered into an exclusive distributor agreement with Genetik, Inc., to market, sell and service the company’s groundbreaking Imagio® Opto-Acoustic/Ultrasound (OA/US) Breast Imaging System.

Key Points: 
  • San Antonio, TX, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Seno Medical has entered into an exclusive distributor agreement with Genetik, Inc., to market, sell and service the company’s groundbreaking Imagio® Opto-Acoustic/Ultrasound (OA/US) Breast Imaging System.
  • This distributor agreement – a first for Seno – will enable Genetik to regionally distribute the Imagio® System in Singapore, where the distributor is headquartered.
  • Seno’s OA/US system combines laser optics and grayscale ultrasound to provide fused functional, morphological, and anatomical breast imaging.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to developing and commercializing a new modality in cancer diagnosis: opto-acoustic imaging.

Retrospective Study of Seno Medical’s Imagio® Breast Imaging System Published in American Journal of Roentgenology Shows System May Help Reduce Biopsies of Benign Breast Masses Compared to Ultrasound Alone

Retrieved on: 
Thursday, January 5, 2023
Cancer, Google Images, American Journal, Gold, Radiology, American Journal of Roentgenology, MD, Certification, Artificial intelligence, Hypoxia, Breast, X-ray, Malignancy, Patient, Minnie Sarwal, Breast mass, Physician, Stavros S Niarchos, Supplement, DST, Seno, Medical imaging

The study, Optoacoustic Imaging with Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study , shows that optoacoustic imaging with decision support may help reduce biopsies of benign breast masses compared with grayscale ultrasound interpretation alone, while maintaining 98 percent sensitivity for cancer.

Key Points: 
  • The study, Optoacoustic Imaging with Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study , shows that optoacoustic imaging with decision support may help reduce biopsies of benign breast masses compared with grayscale ultrasound interpretation alone, while maintaining 98 percent sensitivity for cancer.
  • The reader study included 480 patients with 480 breast masses that had been classified by conventional grayscale ultrasound.
  • Seno’s OA/US system combines laser optics and grayscale ultrasound to provide fused functional, morphological, and anatomical breast imaging.
  • Analysis of utilization patterns and associated costs of the breast imaging and diagnostic procedures after screening mammography.

Seno Medical's Market-Ready Imagio® OA/US Breast Imaging System Launches at RSNA 2022, Booth 6120

Retrieved on: 
Sunday, November 27, 2022
FDA Center for Devices and Radiological Health, US Food Sovereignty Alliance, SAN, Sin senos no hay paraíso, Electronics, Malignancy, Multimedia, Certification, RSNA, CDRH, Artificial intelligence, Physician, Patient, X-ray, Breast mass, Gold, PMA, Annual general meeting, Seno, Device, Google Images, Radiology, FDA, Breast, Medical imaging

SAN ANTONIO, Nov. 27, 2022 /PRNewswire/ -- Seno Medical, makers of the Imagio® Breast Imaging System - a revolutionary new modality in breast imaging - will officially launch the commercially available system at the annual RSNA Scientific Assembly and Annual Meeting starting November 27 through December 1 in Chicago (Booth 6120). Recently recognized with a Gold Edison award, a Gold Medical Design Excellence Award, and as a semifinalist in the Minnies 2022 competition for its medical innovation, Seno's groundbreaking diagnostic breast cancer imaging system helps physicians differentiate between benign and malignant breast lesions using non-invasive opto-acoustic/ultrasound (OA/US) technology to provide information about breast lesions in real time, helping providers to characterize masses that may — or may not — require more invasive diagnostic evaluation.

Key Points: 
  • The category defining Imagio Breast Imaging System helps physicians differentiate between benign and malignant breast lesions using a novel combination of ultrasound and opto-acoustictechnology.
  • SAN ANTONIO, Nov. 27, 2022 /PRNewswire/ -- Seno Medical, makers of the Imagio Breast Imaging System - a revolutionary new modality in breast imaging - will officially launch the commercially available system at the annual RSNA Scientific Assembly and Annual Meeting starting November 27 through December 1 in Chicago (Booth 6120).
  • Seno's OA/US system combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging.
  • Originally approved by the US FDA in January 2021, Seno Medical's Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.

Seno Medical Launches its Scans Across America Mobile Bus Tour for Hands-on Demonstrations Throughout the USA of the Imagio® Breast Imaging System

Retrieved on: 
Tuesday, August 9, 2022
GLOBE, Breast, Cancer, X-ray, Stavros S Niarchos, Patient, Adult, Google Images, Hypoxia, Seno, Radiology, Artificial intelligence, Supplement, Gold, Physician, Breast mass, Certification, Malignancy, Medical imaging

Breast biopsy procedures, caused by false-positive diagnostic assessments, cost the US healthcare system more than $2 billion per year.

Key Points: 
  • Breast biopsy procedures, caused by false-positive diagnostic assessments, cost the US healthcare system more than $2 billion per year.
  • Senos OA/US system combines laser optics and grayscale ultrasound to provide fused functional, morphological, and anatomical breast imaging.
  • The Imagio OA/US Road Show - Scans Across America tour will feature continued stops across the country throughout 2022.
  • Seno Medical Instruments, Inc. is a San Antonio, Texas-based medical imaging company committed to developing and commercializing a new modality in cancer diagnosis: opto-acoustic imaging.

Seno Medical’s Market-Ready Imagio® OA/US Breast Imaging System Receives Supplemental FDA PMA Approval

Retrieved on: 
Tuesday, June 28, 2022
Health, FDA, Artificial intelligence, Hypoxia, Patient, CEO, Adult, Electronics, FDA Center for Devices and Radiological Health, Malignancy, GLOBE, CDRH, PMA, Device, Cancer, X-ray, Radiology, Google Images, Seno, Certification, Breast mass, Breast, US Food Sovereignty Alliance, Physician, Center, Stavros Institute, Medical imaging

San Antonio, TX, June 28, 2022 (GLOBE NEWSWIRE) -- Seno Medicals Imagio Breast Imaging System, a revolutionary new modality in breast imaging, has received supplemental premarket approval (PMA) from the Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA).

Key Points: 
  • San Antonio, TX, June 28, 2022 (GLOBE NEWSWIRE) -- Seno Medicals Imagio Breast Imaging System, a revolutionary new modality in breast imaging, has received supplemental premarket approval (PMA) from the Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA).
  • The Imagio Breast Imaging System incorporates state-of-the-art ultrasound imaging technology required for premier breast imaging centers, as well as advanced ultrasound technology integrated into the opto-acoustic probe, a new ultrasound probe, and elimination of redundant electronics, making this version of Imagio more ergonomic and truly disruptive for the marketplace with the latest technological advances.
  • Senos OA/US system combines laser optics and grayscale ultrasound to provide fused functional and anatomical breast imaging.
  • Originally approved by the US FDA in January 2021, Seno Medicals Imagio Breast Imaging System fuses opto-acoustic technology with ultrasound (OA/US) to generate real-time functional and anatomical images of the breast.